Health outcomes
|
RIF containing regimen (n=3)
|
Antibiotics, other than RIF (n=25)
|
Recovery
|
2 (67%)
|
16 (64%)
|
Lost to follow-up
|
−
|
3 (12%)
|
Dead
|
1 (33%)
|
3 (12%)
|
Relapse
|
−
|
3 (12%)
|
RIF = rifampicin
Source: Meyssonnier et al. (2014)
The second study, a Thai retrospective chart review by Lam et al. (2014), identified that patients with rifampicin-resistant or MDR-TB who received rifampicin-containing Category II treatment (streptomycin, isoniazid, ethambutol, rifampicin, and pyrazinamide) before DST results had poorer treatment outcomes than those who received the treatment post-DST (Table ). Patients who completed treatment and those who were cured of TB were considered to have successful outcomes; patients for whom treatment failed and those who defaulted or died were considered to have poor treatment outcomes. However, it was not reported which combination of antibiotic treatments the ‘no rifampicin’ group received (possibly variable).
Table Association between treatment characteristics and poor treatment outcome among rifampicin-resistant and MDR-TB patients, Thailand 2004–08
Dostları ilə paylaş: |
